Plain-English translation of NCT06493019 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Anal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a research study testing a new way to treat early-stage anal cancer using —a type of immunotherapy drug that helps your immune system fight cancer—combined with two chemotherapy drugs ( and ) and radiation therapy. The goal is to see if this combination works better or has fewer side effects than the current standard treatment for eligible patients.
The current standard treatment for anal cancer can be difficult to tolerate and doesn't work for everyone. This trial is exploring whether adding an immunotherapy drug to the existing chemotherapy and radiation approach might improve outcomes or be easier for patients to handle.
You likely qualify if…
You likely don't qualify if…
You would receive 6 weeks of weekly chemotherapy combined with radiation therapy (the chemoradiation phase), followed by an 8-week maintenance phase where you receive the immunotherapy drug alone every 6 weeks. After that, you'll enter a surveillance period with follow-up visits to monitor your health and check how well the treatment worked. Throughout the trial, you'll have blood tests and imaging scans to track your progress.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States